{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:53:05Z","timestamp":1772632385148,"version":"3.50.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>To provide pediatric clinicians with an overview of current research on leucovorin use in children with autism spectrum disorder (ASD) and a guide to patient evaluation and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>An association between cerebral folate deficiency (CFD) and ASD has been suggested in some studies. Autoantibodies that block folate entry into the brain are a cause of CFD and have been detected in 71% of patients with ASD. Leucovorin is a synthetic drug that increases folate concentrations in the brain despite the presence of autoantibodies. Certain studies have indicated reductions in communication deficits in nonverbal children with ASD, particularly those with these autoantibodies, following consistent leucovorin use. However, other studies have found no change in symptoms despite leucovorin intake. The American Academy of Pediatrics (AAP) currently does not recommend use of leucovorin in children with ASD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Due to recent popularity among policymakers and on social media, many pediatricians have reported increased requests by families for leucovorin prescriptions to treat ASD in pediatric patients. This review provides clinicians with an overview of the biological rationale, clinical evidence, and potential benefits and limitations of leucovorin use in children with ASD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001547","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:00:19Z","timestamp":1770822019000},"page":"207-211","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical concerns and considerations for leucovorin use in autism spectrum disorder"],"prefix":"10.1097","volume":"38","author":[{"given":"Caroline","family":"Howard","sequence":"first","affiliation":[{"name":"Northwell"},{"name":"Cohen Children's Medical Center, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Mekhail","sequence":"additional","affiliation":[{"name":"Northwell"},{"name":"Cohen Children's Medical Center, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian Maidman","family":"Ravikoff","sequence":"additional","affiliation":[{"name":"Northwell"},{"name":"Cohen Children's Medical Center, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Milanaik","sequence":"additional","affiliation":[{"name":"Northwell"},{"name":"Cohen Children's Medical Center, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"R1-20260304","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/mp.2016.168","article-title":"Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial","volume":"23","author":"Frye","year":"2018","journal-title":"Mol Psychiatry"},{"key":"R13-20260304","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1469-8749.2008.02053.x","article-title":"A milk-free diet downregulates folate receptor autoimmunity in cerebral folate deficiency syndrome","volume":"50","author":"Ramaekers","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"R16-20260304","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s41252-020-00157-8","article-title":"An examination of changes in urinary metabolites and behaviors with the use of leucovorin calcium in children with autism spectrum disorder (ASD)","volume":"4","author":"Bent","year":"2020","journal-title":"Adv Neurodev Disord"},{"key":"R17-20260304","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1007\/s00431-024-05762-6","article-title":"Efficacy of oral folinic acid supplementation in children with autism spectrum disorder: a randomized double-blind, placebo-controlled trial","volume":"183","author":"Panda","year":"2024","journal-title":"Eur J Pediatr"},{"key":"R18-20260304","first-page":"282","article-title":"A new form of folic acid\u2014the Leuconostoc citrovorum factor","volume":"8","year":"1950","journal-title":"Nutr Rev"},{"key":"R21-20260304","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1056\/NEJMoa043160","article-title":"Autoantibodies to folate receptors in the cerebral folate deficiency syndrome","volume":"352","author":"Ramaekers","year":"2005","journal-title":"N Engl J Med"},{"key":"R22-20260304","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s10803-007-0492-z","article-title":"Autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency","volume":"38","author":"Moretti","year":"2008","journal-title":"J Autism Dev Disord"},{"key":"R23-20260304","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1055\/s-2008-1065354","article-title":"Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits","volume":"38","author":"Ramaekers","year":"2007","journal-title":"Neuropediatrics"},{"key":"R24-20260304","first-page":"117","article-title":"Lessons from the leucovorin shortages between 2009 and 2012 in a Medicare Advantage population: where do we go from here?","volume":"71","author":"Hayes","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"R26-20260304","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/jpm11111141","article-title":"Cerebral folate deficiency, folate receptor alpha autoantibodies and leucovorin (folinic acid) treatment in autism spectrum disorders: a systematic review and meta-analysis","volume":"11","author":"Rossignol","year":"2021","journal-title":"J Pers Med"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:00:36Z","timestamp":1772607636000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001547","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}